Latest news with #MiriumPharmaceuticals

Globe and Mail

Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, expected to drive market

The Biliary Atresia market growth is driven by factors like increase in the prevalence of Biliary Atresia, investments in research and development, entry of emerging therapies during the study period 2020-2034. The Biliary Atresia market report also offers comprehensive insights into the Biliary Atresia market size, share, Biliary Atresia epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Biliary Atresia market size growth forward. Some of the key highlights from the Biliary Atresia Market Insights Report: Several key pharmaceutical companies, including Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, and others, are developing novel products to improve the Biliary Atresia treatment outlook. DelveInsight estimates that in 2023, there were approximately 609 new cases of biliary atresia across the 7MM. The US accounted for nearly 56% of these cases, while EU4 and the UK represented 28%, and Japan accounted for 16%. The biliary atresia market is poised for steady growth, with a strong compound annual growth rate (CAGR) expected from 2024 to 2034. Key factors driving this market expansion in the US include the increasing incidence of the disease, advancements in diagnostic methods, and growing acceptance of treatments. As a result, the biliary atresia drugs market is projected to experience significant growth, with a CAGR of 7.7%. Despite these advancements, there is still a considerable treatment gap for biliary atresia due to the lack of approved drug therapies, with current treatments primarily relying on surgical procedures like the Kasai operation and liver transplantation. Given the substantial unmet needs in biliary atresia, several promising drugs are currently under development, targeting the condition, including odevixibat and obeticholic acid, among others. As per DelveInsight analysis, the Biliary Atresia market is anticipated to witness growth at a considerable CAGR Strategise your business goals by understanding market dynamics @ Biliary Atresia Market Landscape Biliary Atresia Overview Biliary atresia is a neonatal liver condition characterized by progressive obstruction and fibrosis of the extrahepatic biliary tree, along with fibrosis and inflammation of the liver tissue. The exact cause and mechanisms behind biliary atresia are still unclear. Recent research is exploring potential pathogenic factors, such as genetic predisposition, immune system involvement, and environmental factors like viruses and toxins. It is likely that there isn't a single cause but rather a range of harmful factors that could lead to a common outcome of extrahepatic bile duct obstruction and liver fibrosis. The symptoms of biliary atresia typically emerge between 2 to 6 weeks of age. These include jaundice, which causes a yellowish tint to the skin and the whites of the eyes, pale stools, and dark urine. Infants may also experience abdominal swelling and/or an enlarged liver (hepatomegaly). Do you know the treatment paradigms for different countries? Download our Biliary Atresia Market Sample Report Biliary Atresia Epidemiology Insights DelveInsight's epidemiology model estimates that in 2023, there were approximately 338 new cases of biliary atresia in the US, with this number expected to rise by 2034. In 2023, there were about 17 cases of Type I, 7 cases of Type II, and 315 cases of Type III. Our projections indicate that these case numbers will change over the forecast period from 2024 to 2034. Biliary Atresia Epidemiology Segmentation DelveInsight's Biliary Atresia market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Biliary Atresia historical patient pools and forecasted Biliary Atresia patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Biliary Atresia Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into: Biliary Atresia Prevalence Age-Specific Biliary Atresia Prevalence Gender-Specific Biliary Atresia Prevalence Diagnosed and Treatable Cases of Biliary Atresia Visit for more @ Biliary Atresia Epidemiological Insights Biliary Atresia Market Outlook Biliary atresia is characterized by the fibro-proliferative obliteration of the biliary tree, which progressively leads to hepatic fibrosis, cirrhosis, and eventually end-stage liver failure. The treatment for biliary atresia is primarily surgical and generally involves two stages. In the first few months of life, a Hepatoportoenterostomy (commonly known as the "Kasai" procedure, with possible modifications) is performed to restore biliary flow to the intestine and minimize further liver damage. If this procedure fails or if the disease advances to biliary cirrhosis and life-threatening complications, a liver transplant is required, making biliary atresia the most common pediatric indication for liver transplantation. In terms of postoperative care, management following Hepatoportoenterostomy includes interventions such as the use of choleretics and anti-inflammatory medications, nutritional rehabilitation, supplementation with fat-soluble vitamins, prevention of cholangitis, and management of portal hypertension and its related complications. Administration of choleretics like ursodeoxycholic acid (UDCA) is a standard practice in biliary atresia, although its clinical effectiveness has not been definitively proven. Taken orally, UDCA is a hydrophilic bile acid that alters the balance of bile acids toward hydrophilic forms. This is believed to stabilize cell membranes and reduce the generation of free radicals, thereby protecting mitochondria from damage. High-energy supplements, such as glucose polymers or medium-chain triglyceride (MCT) oil, are added to formula or solid foods to support nutritional needs. MCT oil or MCT-based formulas are particularly useful because they are calorie-dense and can be easily absorbed by patients with cholestasis, as they do not require micellar solubilization. The treatment of biliary atresia is comprehensive, focusing on both addressing the underlying cause and managing symptoms to enhance patient comfort. Biliary Atresia Emerging Drugs BYLVAY (odevixibat): Ipsen Obeticholic Acid: Intercept Pharmaceuticals Biliary Atresia Key Companies Mirium Pharmaceuticals Albireo Intercept Pharmaceuticals, and others For more information, visit Biliary Atresia Market Analysis, Patient Pool, and Emerging Therapies Scope of the Biliary Atresia Market Report: 11 Years Forecast 7MM Coverage Descriptive overview of Biliary Atresia, causes, signs and symptoms, diagnosis, treatment Comprehensive insight into Biliary Atresia epidemiology in the 7MM Biliary Atresia marketed and emerging therapies Biliary Atresia companies Biliary Atresia market drivers and barriers Table of Contents: 1 Biliary Atresia Market Key Comprehensive Insights 2 Biliary Atresia Market Report Introduction 3 Competitive Intelligence Analysis for Biliary Atresia 4 Biliary Atresia Market Analysis Overview at a Glance 5 Executive Summary of Biliary Atresia 6 Biliary Atresia Epidemiology and Market Methodology 7 Biliary Atresia Epidemiology and Patient Population 8 Biliary Atresia Patient Journey 9 Biliary Atresia Treatment Algorithm, Biliary Atresia Current Treatment, and Medical Practices 10 Key Endpoints in Biliary Atresia Clinical Trials 11 Biliary Atresia Marketed Therapies 12 Biliary Atresia Emerging Therapies 13 Biliary Atresia: 7 Major Market Analysis 14 Attribute analysis 15 Access and Reimbursement Overview of Biliary Atresia 16 Biliary Atresia Market Key Opinion Leaders Reviews 18 Biliary Atresia Market Drivers 19 Biliary Atresia Market Barriers 20 SWOT Analysis 21 Disclaimer 22 DelveInsight Capabilities 23 About DelveInsight Related Reports: Biliary Atresia Epidemiology 2034 DelveInsight's "Biliary Atresia - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Biliary Atresia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Biliary Atresia Pipeline 2024 "Biliary Atresia Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Biliary Atresia market. A detailed picture of the Biliary Atresia pipeline landscape is provided, which includes the disease overview and Biliary Atresia treatment guidelines. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Kritika Rehani Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website: